Aurobindo Pharma Limited
https://www.aurobindo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aurobindo Pharma Limited
Finance Watch: VC Mega-Rounds Surge Again, Led By Acelyrin’s $300m Series C
Private Company Edition: Acelyrin will use its latest funding for Phase III development of izokibep in inflammatory diseases. Also, ArsenalBio raised $220m to take its programmable cell therapies into the clinic and RayzeBio’s $160m series D round will fund clinical trials for its radiopharmaceuticals.
Zydus To Slice Into Shrinking Revlimid Pie ‘In Near Term’ As Asacol Revenues Erode
Zydus is set to join Natco in chipping away at BMS’ blockbuster Revlimid with its generic version, probably from Q2 while Aurobindo expects to launch by FY24. Revenues from this drug are expected to offset erosion of generic Asacol revenues even as Zydus expects volume growth and new launches to help grow its US business.
China Halts UCB's Keppra Injection Sales
China halts import, sales and use of the widely prescribed epilepsy drug.
China Halts UCB's Keppra Injection Sales
China halts import, sales and use of the widely prescribed epilepsy drug.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Acrotech Biopharma, LLC
- APL
- Glaxo (India)
- TL Biopharmaceutical AG.